title: [Abdominal presentation of B-cell non-Hodgkin's lymphoma (B-NHL) - surgical treatment and its results. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
abstract: The aim of this study was to analyse the effect of LMB-89 protocol and surgical procedure at initial laparotomy on the outcome in children with abdominal B-cell NHL. The initial surgery intervention was: complete resection (20% pts), subtotal resection (20%), partial resection (4%), biopsy (36%). Postoperative complications occurred in 5 children. Complete recovery (CR) was achieved in 92% pts. There were 4% non responder patients. Two patients died before CR evaluation (tumour lysis syndrome; bleeding and multi organ failure after initial surgery). One patient died in CCR from sepsis probably influenced by the previous local operation. 10.8% patients relapsed. The estimate EFS for all patients with AB-NHL is 81%, 85% for stage III and 73% for stage IV. Major surgery in advanced stages is not recommended since it delays chemotherapy and fails to improve overall survival.
authors.affiliation: Klinika Hematologii, i Chorob Rozrostowych Dzieci, AM we Wrocławiu, ul. Bujwida 44, Poland.
authors.forename: B
authors.initials: B
authors.lastname: Kazanowska
authors.forename: G
authors.initials: G
authors.lastname: Wróbel
authors.forename: W
authors.initials: W
authors.lastname: Jaworski
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: M
authors.initials: M
authors.lastname: Jeleń
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: H
authors.initials: H
authors.lastname: Bubala
authors.forename: A
authors.initials: A
authors.lastname: Dluzniewska
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: A
authors.initials: A
authors.lastname: Kurylak
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: A
authors.initials: A
authors.lastname: Ploszyńska
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sopylo
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
authors.forename: M J
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: K
authors.initials: K
authors.lastname: Stefańska
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: M
authors.initials: M
authors.lastname: Gacka
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007223:Infant; D007813:Laparotomy; D002955:Leucovorin / Q000008:administration & dosage; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate